All Releases
 |
Rockwell Medical Reports Excellent Fourth Quarter and Full Year 2009 Business Results
Mar 10, 2010
|
20.0 KB |
|
| |
Mar 10, 2010 (GlobeNewswire via COMTEX News Network) --
Gross Profit Increases $2.25 million in Q4; Gross Profit up 215% for the
Year
Conference Call at 4:15pm ET to Discuss Results and Review Clinical
Development
WIXOM, Mich., March 10, 2010 (GLOBE NEWSWIRE) ...
|
|
Rockwell Medical Schedules Investor Conference Call
Mar 9, 2010
|
12.8 KB |
|
| |
WIXOM, Mich., Mar 9, 2010 (GlobeNewswire via COMTEX News Network) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, announced today that it will hold an investor conference call o...
|
|
Rockwell Medical Announces Positive Phase IIb Clinical Data
Feb 25, 2010
|
20.0 KB |
|
| |
Feb 25, 2010 (GlobeNewswire via COMTEX News Network) --
SFP Well-Tolerated; No Apparent Toxicity;
Dosing for Phase III Program Determined;
Conference Call February 26, 2010 at 8:30AM EST
WIXOM, Mich., Feb. 25, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrat...
|
|
Rockwell Medical Reports Third Quarter Results; Expanded Gross Profit Margins
Nov 4, 2009
|
17.1 KB |
|
| |
WIXOM, Mich., Nov 4, 2009 (GlobeNewswire via COMTEX News Network) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported today third quarter 2009 sales of $14.2 million, up 4....
|
|
Rockwell Medical Presents New Data on Proprietary Iron-Delivery Drug SFP at American Society of Nephrology Annual Meeting
Nov 2, 2009
|
13.2 KB |
|
| |
WIXOM, MI, Nov 02, 2009 (MARKETWIRE via COMTEX News Network) -- Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, announced today that the Company presented new in vitro data at th...
|
|
Rockwell Medical Completes SFP Phase IIb Clinical Study
Oct 29, 2009
|
11.9 KB |
|
| |
WIXOM, Mich., Oct 29, 2009 (GlobeNewswire via COMTEX News Network) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that the last patient has completed the Phase...
|
|
Rockwell Medical Announces New Corporate Name
Oct 27, 2009
|
11.1 KB |
|
| |
WIXOM, MI, Oct 27, 2009 (MARKETWIRE via COMTEX News Network) -- Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has unveiled a new corporate identity cons...
|
|
Rockwell Medical Schedules Investor Conference Call
Oct 26, 2009
|
12.0 KB |
|
| |
WIXOM, Mich., Oct 26, 2009 (GlobeNewswire via COMTEX News Network) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI) announced today that it will hold an investor conference call on Wednesday, November 4, 2009 at 4:15 p.m. EST to discuss its third quarter results and to provide investors with a business update. Robert Chioini, Chairman and CEO, ...
|
|
Rockwell Medical Technologies, Inc. to Present Abstract At American Society of Nephrology (ASN) Annual Meeting
Oct 13, 2009
|
12.3 KB |
|
| |
WIXOM, Mich., Oct 13, 2009 (GlobeNewswire via COMTEX News Network) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that an abstract on SFP, i...
|
|
Rockwell Medical Technologies, Inc. Appoints Jur Strobos M.D. to Scientific Advisory Board
Oct 6, 2009
|
12.0 KB |
|
| |
WIXOM, Mich., Oct 6, 2009 (GlobeNewswire via COMTEX News Network) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, reported today that it has added Jur Strobo...
|
|
Rockwell Medical Technologies, Inc. Announces Closing of $22 Million Registered Direct Offering of Shares and Warrants
Oct 5, 2009
|
15.5 KB |
|
| |
WIXOM, Mich., Oct 5, 2009 (GlobeNewswire via COMTEX News Network) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has received gross ...
|
|
Rockwell Medical Technologies to Present at the 2009 JMP Securities Healthcare Focus Conference
Oct 1, 2009
|
12.3 KB |
|
| |
WIXOM, Mich. - Rockwell Medical Technologies, Inc. (Nasdaq:
RMTI) a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, today announced that Robert Chioini, Chief Executive Officer, along with Dr. Ajay Gupta, Chief...
|
|
Rockwell Medical Announces $22 Million Registered Direct Offering
Sep 30, 2009
|
12.1 KB |
|
| |
WIXOM, Mich. - Rockwell Medical Technologies, Inc. (Nasdaq:
RMTI) announced today that it has obtained commitments from institutional investors to purchase an aggregate of 2,840,000 shares of Rockwell's common stock and warrants to purchase up to 1,079,200 shares of common stock in a registered direct offering for gross proceeds of approximatel...
|
|
Rockwell Medical Reports Results for Second Quarter 2009
Aug 10, 2009
|
15.1 KB |
|
| |
WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a
fully-integrated biopharmaceutical company offering innovative products and
services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD)
and iron deficiency anemia, reported second quarter 2009 sales of $13.0
million, up 6.8% from $12.2 million in the second quarter of...
|
|
Rockwell Medical Schedules Investor Conference Call
Aug 4, 2009
|
10.5 KB |
|
| |
WIXOM, Mich. - Rockwell Medical Technologies, Inc. (Nasdaq:
RMTI) announced today that it will hold an investor conference call on Monday,
August 10, 2009 at 4:15 p.m. EDT to discuss its second quarter results and to
provide investors with a business update. Robert Chioini, Chairman and CEO, and
Thomas Klema, CFO, will be hosting the call to...
|
|
Rockwell Medical Appoints Ajay Gupta M.D. as Chief Scientific Officer
Jun 30, 2009
|
14.0 KB |
|
| |
WIXOM, Mich. - Rockwell Medical Technologies, Inc. (Nasdaq:
RMTI), a fully-integrated biopharmaceutical company offering innovative
products and services targeting end-stage renal disease (ESRD), chronic kidney
disease (CKD), and iron deficiency anemia, reported today that it has appointed
Ajay Gupta M.D. as its Chief Scientific Officer. Dr....
|
|
Rockwell Medical Technologies Named to Russell Indexes
Jun 29, 2009
|
13.3 KB |
|
| |
WIXOM, Mich. - Rockwell Medical Technologies, Inc. (Nasdaq:
RMTI), a fully-integrated biopharmaceutical company offering innovative
products and services targeting end-stage renal disease (ESRD), chronic kidney
disease (CKD) and iron deficiency anemia, is pleased to announce that it has
been added to the Russell 2000, 2500, 3000 and Global I...
|
|
Rockwell Medical Reports Results for First Quarter 2009
May 11, 2009
|
59.6 KB |
|
| |
WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a
fully-integrated biopharmaceutical company offering innovative products and
services targeting end-stage renal disease (ERSD), chronic kidney disease (CKD)
and iron deficiency anemia, reported first quarter 2009 sales of $12.8 million,
up 3.1% from $12.4 million for the same period of 20...
|
|
Rockwell Medical Schedules Investor Conference Call
Apr 30, 2009
|
10.6 KB |
|
| |
WIXOM, Mich. - Rockwell Medical Technologies, Inc. (Nasdaq:
RMTI) announced today that it will hold an investor conference call on Monday,
May 11, 2009 at 4:15 p.m. EDT to discuss its first quarter results and to
provide investors with a business update. Robert Chioini, Chairman and CEO, and
Thomas Klema, CFO, will be hosting the call to rev...
|
|
Rockwell Medical Announces Patient Enrollment Complete for Phase 2b Dose Range Study
Apr 29, 2009
|
12.3 KB |
|
| |
WIXOM, Mich. - Rockwell Medical Technologies, Inc. (Nasdaq:
RMTI), a fully-integrated biopharmaceutical company offering innovative
products and services targeting end-stage renal disease (ERSD), chronic kidney
disease (CKD), and iron deficiency anemia, reported today that patient
enrollment has been completed for it's ongoing Phase 2b dose-...
|
|
|
=add release to Briefcase |
| Stock Information |
| NASDAQ : RMTI |
|
$6.14
+ 0.22
|
| Delayed at least 20min., by eSignal. |
|
View fact sheet
SFP Mode of Action
|
